nash tirzepatide SYNERGY-NASH: Tirzepatide, a GIP/GLP-1 RA, Resolves MASH Without Worsening Fibrosis Tirzepatide Produces NASH Resolution and

,

2 The FDA approval of Wegovy HD is based on the results of the STEP UP trial program, which included STEP UP, a 72-week study which evaluated the efficacy and safety of once-weekly Wegovy 7.2 mg compared to placebo and Wegovy 2.4 mg, as an adjunct to lifestyle intervention in 1,407 adults with obesity (BMI 30 kg/m 2 or greater), without diabetes

Although both contain semaglutide, compounded semaglutide products are not FDA-approved and have not been tested for safety, effectiveness, or quality in the same way as an FDA-approved drug like Wegovy

We classified prescriptions of Wegovy (approved for overweight and obesity) as on-label if the patient had a history of BMI 27 or documentation of obesity, and off-label otherwise